Goncalo Bernardes received his D.Phil. degree from the University of Oxford. He was awarded a Marie-Curie Fellowship to perform postdoctoral studies with Prof. Peter H. Seeberger in Antibody Drug Conjugation. From September 2010 until October 2012, Gonçalo was an EMBO Fellow in the group of Prof. Dario Neri at the ETH Zürich where he developed novel vascular targeting antibody-drug conjugates (ADCs) for cancer therapy. Since October 2012, Gonçalo is at the Deparment of Chemistry, University of Cambridge, UK where he holds a prestigious Royal Society University Research Fellowship. In addition, he is also the Director of the Chemical Biology and Pharmaceutical Biotechnology Unit at the Instituto de Medicina Molecular (UMM) in Lisbon. His research has resulted in more than 30 peer review publications, 4 patents and he has been invited to present his research in more than 50 conferences/institutes worldwide. Gonçalo has recently been awarded the EFMC Prize for Young Medicinal Chemist in Academia and has been distinguished by the Ministry of Health (MH) of Portugal for relevant services to Public Health and Medicine.

 antibody drug conjugation, cancer therapy, chemistry, biotechnology